[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100305377":3},{"organization":4,"armGroups":7,"interventions":32,"overallOfficials":57,"centralContacts":57,"locations":58,"responsibleParty":76,"collaborators":57,"id":80,"slug":57,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":57,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":57,"studyType":93,"phases":94,"briefSummary":97,"conditions":98,"keywords":57,"overallStatus":60,"whyStopped":57,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"University of Calgary","OTHER",[8,14,20,26],{"label":9,"type":10,"description":11,"interventionNames":12},"CBF Lowering and Normoxia Sleep","ACTIVE_COMPARATOR","Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.",[13],"Drug: Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep",{"label":15,"type":16,"description":17,"interventionNames":18},"CBF Lowering and IH Sleep","EXPERIMENTAL","Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.",[19],"Drug: Drug Lowering CBF and Intermittent Hypoxia Sleep",{"label":21,"type":22,"description":23,"interventionNames":24},"Placebo and Normoxia Sleep","SHAM_COMPARATOR","Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.",[25],"Drug: Placebo and Normoxia Sleep",{"label":27,"type":28,"description":29,"interventionNames":30},"Placebo and IH Sleep","PLACEBO_COMPARATOR","Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.",[31],"Drug: Placebo and Intermittent Hypoxia Sleep",[33,40,46,51],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"DRUG","Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep","The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Normoxia Exposure",[9],[39],"Cerebral Blood Flow changes and Normoxia Sleep",{"type":34,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"Drug Lowering CBF and Intermittent Hypoxia Sleep","The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Intermittent Hypoxia (IH) Exposure",[15],[45],"CBF changes and Intermittent Hypoxia Sleep",{"type":34,"name":21,"description":47,"armGroupLabels":48,"otherNames":49},"The study participants will take Placebo and sleep under Normoxia Exposure",[21],[50],"Cerebral Blood Flow (CBF) with Placebo in Normoxia Sleep",{"type":34,"name":52,"description":53,"armGroupLabels":54,"otherNames":55},"Placebo and Intermittent Hypoxia Sleep","The study participants will take Placebo and sleep under Intermittent Hypoxia (IH) Exposure",[27],[56],"CBF with Placebo in Intermittent Hypoxia Sleep",null,[59],{"facility":5,"status":60,"city":61,"state":62,"zip":63,"country":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"RECRUITING","Calgary","Alberta","T2N 4N1","Canada",{"type":66,"coordinates":67},"Point",[68,69],-114.08529,51.05011,{"lat":69,"lon":68},[72],{"name":73,"role":74,"phone":75,"phoneExt":57,"email":57},"Chair, Conjoint Ethics Board","CONTACT","chreb@ucalgary.ca",{"type":77,"investigatorFullName":78,"investigatorTitle":79,"investigatorAffiliation":5,"oldNameTitle":57,"oldOrganization":57},"PRINCIPAL_INVESTIGATOR","Marc Poulin","PhD, DPhil, Professor","100305377",false,"NCT03255408","Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia","Role of Cerebral Blood Flow on Ventilatory Stability During Sleep in Normoxia and Intermittent Hypoxia","Inclusion Criteria:\n\n* Healthy adults\n* 18 - 45 years of age\n* Living in Calgary for the past one year\n* Have no medical condition or should not be taking any blood pressure medications.\n* The participant should not be lactose intolerant\n\nExclusion Criteria:\n\n* Cerebrovascular, cardio-respiratory, renal and metabolic diseases\n* Bleeding disorders and upper gastrointestinal diseases e.g. peptic ulcer disease\n* Pregnancy, obese and sleep-disordered breathing\n* Drug allergies to non-steroidal anti-inflammatories\n* Currently smoking",true,"ALL","18 Years","45 Years",{"count":91,"type":92},12,"ESTIMATED","INTERVENTIONAL",[95,96],"PHASE1","PHASE2","A prospective double blind, placebo-controlled, randomized cross-over trial to evaluate the effect of lowering cerebral blood flow on the ventilatory chemoreflexes (acute hypoxic and hypercapnic ventilatory responses).",[99,100,101,102,103,104,105,106],"Obstructive Sleep Apnea of Adult","Hypoxia, Brain","Sleep Apnea","Sleep Disorder","Stroke","Blood Pressure","Endothelial Dysfunction","Oxidative Stress","2026-04-27",{"date":109,"type":110},"2026-05-01","ACTUAL",{"date":112,"type":110},"2023-01-01",{"date":114,"type":92},"2027-12-30",{"name":5,"class":6},1]